These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 37266425)

  • 1. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.
    Mehdi SF; Pusapati S; Anwar MS; Lohana D; Kumar P; Nandula SA; Nawaz FK; Tracey K; Yang H; LeRoith D; Brownstein MJ; Roth J
    Front Immunol; 2023; 14():1148209. PubMed ID: 37266425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
    Lee YS; Jun HS
    Mediators Inflamm; 2016; 2016():3094642. PubMed ID: 27110066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds.
    Insuela DBR; Carvalho VF
    Eur J Pharmacol; 2017 Oct; 812():64-72. PubMed ID: 28688914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.
    Hogan AE; Gaoatswe G; Lynch L; Corrigan MA; Woods C; O'Connell J; O'Shea D
    Diabetologia; 2014 Apr; 57(4):781-4. PubMed ID: 24362727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B
    Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ
    Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J; Williams NT
    Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
    Hogan AE; Tobin AM; Ahern T; Corrigan MA; Gaoatswe G; Jackson R; O'Reilly V; Lynch L; Doherty DG; Moynagh PN; Kirby B; O'Connell J; O'Shea D
    Diabetologia; 2011 Nov; 54(11):2745-54. PubMed ID: 21744074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.
    Drucker DJ; Rosen CF
    Diabetologia; 2011 Nov; 54(11):2741-4. PubMed ID: 21892687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice.
    Viby NE; Isidor MS; Buggeskov KB; Poulsen SS; Hansen JB; Kissow H
    Endocrinology; 2013 Dec; 154(12):4503-11. PubMed ID: 24092637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.
    Alavi SE; Cabot PJ; Moyle PM
    Mol Pharm; 2019 Jun; 16(6):2278-2295. PubMed ID: 31050435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.